The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.

Three out of four patients with primary (light chain) amyloid nephrotic syndrome treated with vincristine, doxorubicin and dexamethasone (VAD) induction obtained a partial response and are alive in continuing remission at 4.1, 6.5 and 9.3 years. These preliminary results are of considerable interest...

Descripción completa

Detalles Bibliográficos
Autores principales: Wardley, A. M., Jayson, G. C., Goldsmith, D. J., Venning, M. C., Ackrill, P., Scarffe, J. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062981/
https://www.ncbi.nlm.nih.gov/pubmed/9743299
_version_ 1782137242824736768
author Wardley, A. M.
Jayson, G. C.
Goldsmith, D. J.
Venning, M. C.
Ackrill, P.
Scarffe, J. H.
author_facet Wardley, A. M.
Jayson, G. C.
Goldsmith, D. J.
Venning, M. C.
Ackrill, P.
Scarffe, J. H.
author_sort Wardley, A. M.
collection PubMed
description Three out of four patients with primary (light chain) amyloid nephrotic syndrome treated with vincristine, doxorubicin and dexamethasone (VAD) induction obtained a partial response and are alive in continuing remission at 4.1, 6.5 and 9.3 years. These preliminary results are of considerable interest and suggest that prospective evaluation of this regimen is warranted in patients with this condition.
format Text
id pubmed-2062981
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group|1
record_format MEDLINE/PubMed
spelling pubmed-20629812009-09-10 The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Wardley, A. M. Jayson, G. C. Goldsmith, D. J. Venning, M. C. Ackrill, P. Scarffe, J. H. Br J Cancer Research Article Three out of four patients with primary (light chain) amyloid nephrotic syndrome treated with vincristine, doxorubicin and dexamethasone (VAD) induction obtained a partial response and are alive in continuing remission at 4.1, 6.5 and 9.3 years. These preliminary results are of considerable interest and suggest that prospective evaluation of this regimen is warranted in patients with this condition. Nature Publishing Group|1 1998-09 /pmc/articles/PMC2062981/ /pubmed/9743299 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Wardley, A. M.
Jayson, G. C.
Goldsmith, D. J.
Venning, M. C.
Ackrill, P.
Scarffe, J. H.
The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.
title The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.
title_full The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.
title_fullStr The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.
title_full_unstemmed The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.
title_short The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.
title_sort treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062981/
https://www.ncbi.nlm.nih.gov/pubmed/9743299
work_keys_str_mv AT wardleyam thetreatmentofnephroticsyndromecausedbyprimarylightchainamyloidwithvincristinedoxorubicinanddexamethasone
AT jaysongc thetreatmentofnephroticsyndromecausedbyprimarylightchainamyloidwithvincristinedoxorubicinanddexamethasone
AT goldsmithdj thetreatmentofnephroticsyndromecausedbyprimarylightchainamyloidwithvincristinedoxorubicinanddexamethasone
AT venningmc thetreatmentofnephroticsyndromecausedbyprimarylightchainamyloidwithvincristinedoxorubicinanddexamethasone
AT ackrillp thetreatmentofnephroticsyndromecausedbyprimarylightchainamyloidwithvincristinedoxorubicinanddexamethasone
AT scarffejh thetreatmentofnephroticsyndromecausedbyprimarylightchainamyloidwithvincristinedoxorubicinanddexamethasone
AT wardleyam treatmentofnephroticsyndromecausedbyprimarylightchainamyloidwithvincristinedoxorubicinanddexamethasone
AT jaysongc treatmentofnephroticsyndromecausedbyprimarylightchainamyloidwithvincristinedoxorubicinanddexamethasone
AT goldsmithdj treatmentofnephroticsyndromecausedbyprimarylightchainamyloidwithvincristinedoxorubicinanddexamethasone
AT venningmc treatmentofnephroticsyndromecausedbyprimarylightchainamyloidwithvincristinedoxorubicinanddexamethasone
AT ackrillp treatmentofnephroticsyndromecausedbyprimarylightchainamyloidwithvincristinedoxorubicinanddexamethasone
AT scarffejh treatmentofnephroticsyndromecausedbyprimarylightchainamyloidwithvincristinedoxorubicinanddexamethasone

Ejemplares similares